Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Among authors: cathelineau x. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.
Current, new and novel therapy for castration-resistant prostate cancer.
Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X. Gaya JM, et al. Among authors: cathelineau x. Expert Rev Anticancer Ther. 2013 Jul;13(7):819-27. doi: 10.1586/14737140.2013.811154. Expert Rev Anticancer Ther. 2013. PMID: 23875660 Review.
Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma.
Masson-Lecomte A, Colin P, Bozzini G, Nison L, de La Taille A, Comperat E, Zerbib M, Rozet F, Cathelineau X, Valeri A, Ruffion A, Guy L, Droupy S, Cussenot O, Rouprêt M. Masson-Lecomte A, et al. Among authors: cathelineau x. World J Urol. 2014 Apr;32(2):531-7. doi: 10.1007/s00345-013-1141-0. Epub 2013 Aug 2. World J Urol. 2014. PMID: 23907662
Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy.
Hurel S, Rouprêt M, Seisen T, Comperat E, Phé V, Droupy S, Audenet F, Pignot G, Cathelineau X, Guy L, Cussenot O, Ouzzane A, Bozzini G, Nison L, Ruffion A, Colin P. Hurel S, et al. Among authors: cathelineau x. World J Urol. 2015 Mar;33(3):335-41. doi: 10.1007/s00345-014-1311-8. Epub 2014 May 9. World J Urol. 2015. PMID: 24810657
Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Beauval JB, Ploussard G, Cabarrou B, Roumiguié M, Ouzzane A, Gas J, Goujon A, Marcq G, Mathieu R, Vincendeau S, Cathelineau X, Mongiat-Artus P, Salomon L, Soulié M, Méjean A, de La Taille A, Rouprêt M, Rozet F; Committee of Cancerology of the Association of French Urology. Beauval JB, et al. Among authors: cathelineau x. World J Urol. 2017 Aug;35(8):1191-1197. doi: 10.1007/s00345-016-1979-z. Epub 2016 Dec 16. World J Urol. 2017. PMID: 27987030
Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti A, Buttard B, Bourass S, Germain C, Cathelineau X, Fridman WH, Sautès-Fridman C. Giraldo NA, et al. Among authors: cathelineau x. Clin Cancer Res. 2017 Aug 1;23(15):4416-4428. doi: 10.1158/1078-0432.CCR-16-2848. Epub 2017 Feb 17. Clin Cancer Res. 2017. PMID: 28213366
[Ablative therapy in kidney cancer: Indications].
Tricard T, Tsoumakidou G, Lindner V, Garnon J, Albrand G, Cathelineau X, Gangi A, Lang H. Tricard T, et al. Among authors: cathelineau x. Prog Urol. 2017 Nov;27(15):926-951. doi: 10.1016/j.purol.2017.07.245. Epub 2017 Aug 30. Prog Urol. 2017. PMID: 28869173 Review. French.
[Ablative therapy in urology: Good practice and perspective].
Gangi A, Cathelineau X, Tricard T, Lang H. Gangi A, et al. Among authors: cathelineau x. Prog Urol. 2017 Nov;27(15):994-1014. doi: 10.1016/j.purol.2017.08.008. Epub 2017 Sep 27. Prog Urol. 2017. PMID: 28958771 Review. French.
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C, Louvet C, Charton E, Rozet F, Ropert S, Prapotnich D, Barret E, Sanchez-Salas R, Mombet A, Cathala N, Joulia ML, Molitor JL, Henriques J, Bonnetain F, Cathelineau X, Bennamoun M. Fenioux C, et al. Among authors: cathelineau x. BJU Int. 2019 Feb;123(2):300-306. doi: 10.1111/bju.14511. Epub 2018 Sep 4. BJU Int. 2019. PMID: 30099821
268 results